PE20011177A1 - 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE - Google Patents
5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINEInfo
- Publication number
- PE20011177A1 PE20011177A1 PE2001000216A PE2001000216A PE20011177A1 PE 20011177 A1 PE20011177 A1 PE 20011177A1 PE 2001000216 A PE2001000216 A PE 2001000216A PE 2001000216 A PE2001000216 A PE 2001000216A PE 20011177 A1 PE20011177 A1 PE 20011177A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pyrimidines
- methyl
- alkylpyride
- cycline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A DERIVADOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS DE FORMULA I DONDE R2 ES H, ALQUILO, CARBOCICLICO C3-C7; R3 ES H, ALQUILO, ALCOXI, HALOGENO, TRIFLUOROMETILO, ALQUINILO, ALQUENILO, ENTRE OTROS; Y ES N, CR7; R9 ES ALQUILO, HALOALQUILO, ARILO; X Y Z SON H, HALOGENO, ALQUILO, ALCOXI, TRIFLUOROMETILO, HIDROXI, NITRILO, NR4R5, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, ALQUENILO, ALQUINILO, (CH2)nAr, ARILALQUILO, ARILO, HETEROARILO, HETEROARILALQUILO, ENTRE OTROS; R7 ES NR4R5, N(O)R4R5, OH, OR4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 8-CICLOPENTIL-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-(1-METILETIL)-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-CICLOPENTIL-5-METIL-2-(4-FLUORO-3-METIL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA, ENTRE OTROS. LOS COMPUESTOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORES DE TIROSINA CINASAS DEPENDIENTES DE CICLINA (Cdk) Y SON UTILES PARA EL TRATAMIENTO DE INFLAMACION, ENFERMEDADES PROLIFERATIVAS, CANCER, RESTENOSIS, ENFERMEDADES NEURODEGENERATIVASREFERS TO DERIVATIVES OF 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES OF FORMULA I WHERE R2 IS H, ALKYL, CARBOCYCLIC C3-C7; R3 IS H, ALKYL, ALCOXY, HALOGEN, TRIFLUOROMETHYL, ALKINYL, ALKENYL, AMONG OTHERS; Y IS N, CR7; R9 IS ALKYL, HALOALKYL, ARYL; X AND Z ARE H, HALOGEN, ALKYL, ALCOXY, TRIFLUOROMETHYL, HYDROXY, NITRILE, NR4R5, AMONG OTHERS; R4 AND R5 ARE H, ALKYL, ALKENYL, ALKINYL, (CH2) nAr, ARYLALKYL, ARYL, HETEROARYL, HETEROARYALKYL, AMONG OTHERS; R7 IS NR4R5, N (O) R4R5, OH, OR4, AMONG OTHERS. PREFERRED COMPOUNDS ARE 8-CYCLOPENTIL-5-METHYL-2- (4-PIPERAZIN-1-IL-PHENYLAMINE) -8H-PYRIDO [2,3] PYRIMIDIN-7-ONA, 8- (1-METHYLETHYL) -5-METHYL -2- (4-PIPERAZIN-1-IL-PHENYLAMINE) -8H-PYRIDO [2,3] PYRIMIDIN-7-ONA, 8-CYCLOPENTIL-5-METHYL-2- (4-FLUORO-3-METHYL-PHENYLAMINE) -8H-PIRIDO [2,3] PYRIMIDIN-7-ONA, AMONG OTHERS. THE COMPOUNDS OF 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLINE-DEPENDENT TYROSINE KINASES (Cdk) AND ARE USEFUL FOR THE TREATMENT OF INFLAMMATION, PROLIFERATIVE DISEASES, CANCER, RESTENADESIS, ILLNESS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18712400P | 2000-03-06 | 2000-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011177A1 true PE20011177A1 (en) | 2001-11-23 |
Family
ID=22687699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000216A PE20011177A1 (en) | 2000-03-06 | 2001-03-05 | 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1268476A1 (en) |
| JP (1) | JP2003528101A (en) |
| KR (1) | KR20020075805A (en) |
| CN (1) | CN1422268A (en) |
| AP (1) | AP2002002643A0 (en) |
| AR (1) | AR034119A1 (en) |
| AU (1) | AU2001233028A1 (en) |
| BG (1) | BG107161A (en) |
| BR (1) | BR0109056A (en) |
| CA (1) | CA2401368A1 (en) |
| CO (1) | CO5280200A1 (en) |
| CR (1) | CR6736A (en) |
| CZ (1) | CZ20022929A3 (en) |
| DZ (1) | DZ3308A1 (en) |
| EA (1) | EA200200802A1 (en) |
| EE (1) | EE200200506A (en) |
| GT (1) | GT200100037A (en) |
| HN (1) | HN2001000040A (en) |
| HR (1) | HRP20020798A2 (en) |
| HU (1) | HUP0300136A2 (en) |
| IL (1) | IL151480A0 (en) |
| IS (1) | IS6524A (en) |
| MA (1) | MA26881A1 (en) |
| MX (1) | MXPA02008535A (en) |
| NO (1) | NO20024235L (en) |
| NZ (1) | NZ520962A (en) |
| OA (1) | OA12227A (en) |
| PA (1) | PA8513201A1 (en) |
| PE (1) | PE20011177A1 (en) |
| PL (1) | PL358271A1 (en) |
| SK (1) | SK12472002A3 (en) |
| SV (1) | SV2001000338A (en) |
| TN (1) | TNSN01036A1 (en) |
| WO (1) | WO2001070741A1 (en) |
| YU (1) | YU66502A (en) |
| ZA (1) | ZA200207110B (en) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| CZ20031125A3 (en) | 2000-10-23 | 2003-10-15 | Smithkline Beecham Corporation | Novel compounds |
| ATE305303T1 (en) * | 2001-02-12 | 2005-10-15 | Hoffmann La Roche | 6-SUBSTITUTED PYRIDOPYRIMIDINES |
| EP1364950A4 (en) * | 2001-02-26 | 2005-03-09 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
| US20030105115A1 (en) * | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
| US20030100572A1 (en) * | 2001-06-21 | 2003-05-29 | Ariad Pharmaceuticals,Inc. | Novel pyridopyrimidones and uses thereof |
| CN101001857B (en) * | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
| PL373339A1 (en) | 2002-04-19 | 2005-08-22 | Smithkline Beecham Corporation | Novel compounds |
| AU2003250701A1 (en) | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| AU2003273675A1 (en) | 2002-10-09 | 2004-05-04 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| DE602004021558D1 (en) * | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| US8362017B2 (en) | 2003-08-29 | 2013-01-29 | Exelixis, Inc. | C-kit modulators and methods of use |
| ATE356124T1 (en) | 2003-11-13 | 2007-03-15 | Hoffmann La Roche | HYDROXYALKYL SUBSTITUTED PYRIDO-7-PYRIMIDINE-7-ONE |
| DE102004029784A1 (en) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments |
| DE102004033670A1 (en) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pyridodihydropyrazinone, process for its preparation and its use as a medicament |
| FR2873118B1 (en) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| EP1630163A1 (en) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, methods for their preparation and their use as drugs |
| WO2006021547A1 (en) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| DE102004058337A1 (en) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of fused piperazin-2-one derivatives |
| WO2006076706A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
| AR053346A1 (en) | 2005-03-25 | 2007-05-02 | Glaxo Group Ltd | COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38 |
| EA200702073A1 (en) | 2005-03-25 | 2008-12-30 | Глэксо Груп Лимитед | Method of producing pyrido [2,3-d] pyrimidine-7-bp and 3,4-dihidropyrimido [4,5-d] pyrmidin-2 (1h) -onovy derivatives |
| UY29439A1 (en) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | NEW COMPOUNDS |
| JP2008535822A (en) | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | New compounds |
| US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| FR2887882B1 (en) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
| US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
| WO2007044813A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
| WO2007044698A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
| FR2896246B1 (en) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| MX2009002927A (en) | 2006-09-15 | 2009-03-31 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors. |
| JP2010506902A (en) * | 2006-10-16 | 2010-03-04 | ジーピーシー・バイオテック・インコーポレーテッド | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2008055013A2 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| FR2910813B1 (en) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA |
| UA101611C2 (en) * | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | Compounds of imidazo[1,2-a]pyridine as receptor tyrosine kinase inhibitors |
| EP2168966B1 (en) | 2007-06-15 | 2016-09-28 | Msd K.K. | Bicycloaniline derivative |
| CA2695406A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| KR20100095020A (en) | 2007-12-19 | 2010-08-27 | 암젠 인크 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| EP2225226B1 (en) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
| EP2100894A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| ATE531372T1 (en) * | 2008-04-07 | 2011-11-15 | Amgen Inc | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINOPYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| AR073524A1 (en) | 2008-09-30 | 2010-11-10 | Exelixis Inc | PI3K A AND M TOR INHIBITING PYRIDOPIRIMIDINONES |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| JP2013507395A (en) * | 2009-10-09 | 2013-03-04 | アフラクシス・インコーポレイテッド | 8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidin-7 (8H) -one for the treatment of CNS disorders |
| CA2784749C (en) * | 2009-12-18 | 2017-12-12 | E. Premkumar Reddy | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
| US8901137B2 (en) | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
| EA022527B1 (en) * | 2010-08-05 | 2016-01-29 | Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| JP6000273B2 (en) | 2010-11-29 | 2016-09-28 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Macrocyclic kinase inhibitor |
| PT2688887E (en) | 2011-03-23 | 2015-07-06 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| AU2012255860C1 (en) * | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| EP2817308B1 (en) * | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| PL2958916T3 (en) * | 2013-02-21 | 2019-01-31 | Pfizer Inc. | Solid forms of a selective cdk4/6 inhibitor |
| WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| EP3172214B1 (en) | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| TWI646094B (en) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| JP6563623B1 (en) | 2016-08-15 | 2019-08-21 | ファイザー・インク | Pyridopyrimidinone CDK2 / 4/6 inhibitor |
| EP3589634A4 (en) * | 2017-03-03 | 2020-08-12 | Auckland Uniservices Limited | Fgfr kinase inhibitors and pharmaceutical uses |
| AU2019220746A1 (en) | 2018-02-15 | 2020-08-27 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| US20220024916A1 (en) * | 2018-12-07 | 2022-01-27 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic comipound as cdk-hdac dual pathway inhibitor |
| CN112759589B (en) * | 2019-11-01 | 2022-04-08 | 暨南大学 | Pyrimidopyridinones and their use |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| AU2022234998A1 (en) * | 2021-03-08 | 2023-10-12 | Jinan University | Pyridopyrimidine compounds and applications thereof |
| WO2024056091A1 (en) * | 2022-09-16 | 2024-03-21 | 华东师范大学 | Pyridonopyrimidine derivative as rsk inhibitor and use thereof |
| WO2024099403A1 (en) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| EP0964864B1 (en) * | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| EP1080092B1 (en) * | 1998-05-26 | 2008-07-23 | Warner-Lambert Company LLC | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
-
2001
- 2001-01-29 IL IL15148001A patent/IL151480A0/en unknown
- 2001-01-29 EE EEP200200506A patent/EE200200506A/en unknown
- 2001-01-29 CA CA002401368A patent/CA2401368A1/en not_active Abandoned
- 2001-01-29 OA OA1200200281A patent/OA12227A/en unknown
- 2001-01-29 MX MXPA02008535A patent/MXPA02008535A/en not_active Application Discontinuation
- 2001-01-29 HU HU0300136A patent/HUP0300136A2/en unknown
- 2001-01-29 BR BR0109056-9A patent/BR0109056A/en not_active IP Right Cessation
- 2001-01-29 NZ NZ520962A patent/NZ520962A/en unknown
- 2001-01-29 EP EP01905114A patent/EP1268476A1/en not_active Withdrawn
- 2001-01-29 PL PL01358271A patent/PL358271A1/en not_active Application Discontinuation
- 2001-01-29 SK SK1247-2002A patent/SK12472002A3/en unknown
- 2001-01-29 YU YU66502A patent/YU66502A/en unknown
- 2001-01-29 EA EA200200802A patent/EA200200802A1/en unknown
- 2001-01-29 CZ CZ20022929A patent/CZ20022929A3/en unknown
- 2001-01-29 KR KR1020027011627A patent/KR20020075805A/en not_active Application Discontinuation
- 2001-01-29 DZ DZ013308A patent/DZ3308A1/en active
- 2001-01-29 AP APAP/P/2002/002643A patent/AP2002002643A0/en unknown
- 2001-01-29 WO PCT/US2001/002657 patent/WO2001070741A1/en active IP Right Grant
- 2001-01-29 AU AU2001233028A patent/AU2001233028A1/en not_active Abandoned
- 2001-01-29 CN CN01807590A patent/CN1422268A/en active Pending
- 2001-01-29 JP JP2001568942A patent/JP2003528101A/en not_active Abandoned
- 2001-03-02 TN TNTNSN01036A patent/TNSN01036A1/en unknown
- 2001-03-05 CO CO01017398A patent/CO5280200A1/en not_active Application Discontinuation
- 2001-03-05 GT GT200100037A patent/GT200100037A/en unknown
- 2001-03-05 PA PA20018513201A patent/PA8513201A1/en unknown
- 2001-03-05 AR ARP010101039A patent/AR034119A1/en unknown
- 2001-03-05 SV SV2001000338A patent/SV2001000338A/en not_active Application Discontinuation
- 2001-03-05 PE PE2001000216A patent/PE20011177A1/en not_active Application Discontinuation
- 2001-03-05 HN HN2001000040A patent/HN2001000040A/en unknown
-
2002
- 2002-08-23 CR CR6736A patent/CR6736A/en not_active Application Discontinuation
- 2002-08-23 IS IS6524A patent/IS6524A/en unknown
- 2002-09-04 ZA ZA200207110A patent/ZA200207110B/en unknown
- 2002-09-04 MA MA26801A patent/MA26881A1/en unknown
- 2002-09-05 NO NO20024235A patent/NO20024235L/en not_active Application Discontinuation
- 2002-10-02 BG BG107161A patent/BG107161A/en unknown
- 2002-10-04 HR HR20020798A patent/HRP20020798A2/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011177A1 (en) | 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE | |
| EA200500721A1 (en) | Pyrimidines inhibiting CHK, PDK and ACT, THEIR RECEIVING AND USING AS MEDICINES | |
| PE20030975A1 (en) | 2- (PYRIDIN-2-ILAMINO) -PYRIDO [2,3-d] PYRIMIDIN-7-ONAS | |
| PE20021096A1 (en) | DERIVATIVES OF 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PIRROLO [2,3-D] PYRIMIDINE AS INHIBITORS OF IGF-IR TYROSINE-KINASE | |
| PE20021010A1 (en) | SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS | |
| UY27714A1 (en) | 2 - HETEROARIL - CDK INHIBITING PYRIMIDINES, ITS PREPARATION AND ITS USE AS MEDICATIONS. | |
| ECSP034831A (en) | SUBSTITUTED DERIVATIVES OF 2-PYRIDINE CYCLHEXAN-1,4-DIAMINE | |
| MXPA02011426A (en) | bgr; CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE. | |
| ES2195785B1 (en) | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. | |
| UY27604A1 (en) | CHEMICAL COMPOUNDS. | |
| HN2002000067A (en) | INHIBITORS OF THE RHO - QUINASA. | |
| PE20060504A1 (en) | PYRIMIDINE DERIVATIVES IN THE TREATMENT OF CANCER | |
| UY26782A1 (en) | DERIVATIVES OF BENZOTIAZOLE | |
| BR0206633A (en) | 1-Aryl- or 1-Arylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| CU23148A3 (en) | AZAPOLICICLIC COMPOUNDS CONDENSED WITH ARILO | |
| PA8432901A1 (en) | PIRIDILPIRROL COMPOUNDS | |
| PE20030735A1 (en) | BENZOTHIAZOLE DERIVATIVES | |
| PE20030739A1 (en) | ADENOSINE A2A RECEPTOR ANTAGONISTS | |
| SV2003001173A (en) | 1-RENT OR 1-CICLOALQUIL-TRIAZOLO [4,3-A] QUINAZOLIN-5- WAVES AS PHOSPHODIESTERASE INHIBITORS | |
| PE20020594A1 (en) | ARIL-SUBSTITUTED INDIRUBIN DERIVATIVES, THEIR PREPARATION AND USE | |
| BR0215151A (en) | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
| CO5170529A1 (en) | DERIVATIVES OF 5- (REPLACED PHENYL) -2-PIPERAZINIL-PIRIMIDIN- (3,5- BISTRIFLUORO-METIL-BENCIL) -METIL-AMIDA | |
| ATE346067T1 (en) | CARBOLINE DERIVATIVES | |
| ECSP034917A (en) | NEW DERIVATIVES OF SULFONIC ACID | |
| RS53211B (en) | PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES, PROCES FOR THEIR PREPRATION AND THEIR THERAPEUTICAL USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |